Bortetrust 2 Bortezomib 2mg Injection

Bortetrust Bortezomib 2mg Injection is a chemotherapy drug used primarily in the treatment of multiple myeloma and mantle cell lymphoma. It contains bortezomib, a proteasome inhibitor that works by blocking the action of the proteasome, an enzyme complex responsible for breaking down proteins within cells. This action helps stop the growth of cancer cells and may promote their death.

Bortetrust Bortezomib 2mg Injection interferes with the normal functioning of the proteasome, which is needed to maintain the balance of proteins inside cells. By inhibiting the proteasome, bortezomib disrupts the breakdown of damaged proteins, leading to their accumulation in cancer cells. This accumulation triggers a series of events that ultimately cause cancer cells to die, slowing disease progression.

• Multiple Myeloma: A type of cancer that affects plasma cells, a type of white blood cell found in the bone marrow. Bortezomib helps manage the disease by stopping the growth of cancerous plasma cells.
• Mantle Cell Lymphoma (MCL): A rare and aggressive form of non-Hodgkin lymphoma, where bortezomib is used to treat patients whose previous treatments have failed.

Bortezomib 2mg Injection is typically administered intravenously (IV) or subcutaneously (under the skin), with dosage and schedule depending on the patient’s specific condition and treatment regimen. It is usually given in cycles, allowing the body to recover between treatments.

As with most cancer treatments, Bortezomib may cause side effects. Common side effects include:

• Nausea and vomiting
• Fatigue
• Diarrhea or constipation
• Peripheral neuropathy (nerve damage, especially in the hands and feet)
• Low blood cell counts, which can cause anemia, increase the risk of infection, or bleeding

Patients are closely monitored during treatment to manage these side effects effectively.

• Peripheral neuropathy: Bortezomib can cause nerve damage, causing symptoms such as numbness, tingling, or pain, which may worsen with each dose. Patients should notify their doctor if they experience these symptoms.
• Pregnancy and breastfeeding: This medicine should not be used during pregnancy as it may harm the unborn baby. It is also advised not to breastfeed during the treatment.
• Infection risk: Due to its effects on the immune system, bortezomib may increase the risk of infection, so patients should be monitored for signs of infection during treatment.

Bortetrust Bortezomib 2mg Injection is an important therapeutic agent in the treatment of multiple myeloma and mantle cell lymphoma. By inhibiting the proteasome, it helps control the growth of cancer cells and manage symptoms. As with any chemotherapy agent, careful monitoring and management of side effects is essential for optimal treatment outcomes.

Check this Anti Cancer product Bortezomib 2mg Injection Bortemap or you may explore more Anti Cancer products by clicking here

We are an exporter from India and work in many countries, such as the UAE, Oman, Qatar, Myanmar, Saudi Arabia, the Netherlands, Albania, Saint Lucia, Jordan, Romania, and South Africa.